How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Items 701–800 of 1,024
Machine Learning Prediction of Allosteric Drug Activity from Molecular Dynamics
Marchetti, F., Moroni, E., Pandini, A., & Colombo, G. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c00045 · Cited by 65
“The extraordinary complexity of biochemical networks in healthy and disease conditions 3,4 and the costs associated with drug discovery are however hampering the advent of this new era of therapeutics, as shown by the relatively low numbers of new drugs approved in the past few years.”
BackgroundNew horizons for antiviral drug discovery from virus–host protein interaction networks
de Chassey, B., Meyniel‐Schicklin, L., Aublin‐Gex, A., André, P., & Lotteau, V. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.09.001 · Cited by 71
Müller, C. E., Schiedel, A. C., & Baqi, Y. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.06.002 · Cited by 76
“It is estimated that about 30% of marketed drugs interact with GPCRs, although for only less than 10% of the known GPCRs have drugs been clinically developed so far (Overington et al., 2006).”
New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition
van der Schoor, L. W. E., Verkade, H. J., Kuipers, F., & Jonker, J. W. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.981152 · Cited by 71
“In case of NRs activated by xenobiotics, these sequences are also called xenobiotic response elements, usually consisting of six nucleotides [159].”
BackgroundAshtawy, H. M., & Mahapatra, N. R. (2015) · BMC Bioinformatics · doi:10.1186/1471-2105-16-s4-s8 · Cited by 62
“It has been observed that around 92% of existing drug targets are similar to proteins already present in the Protein Data Bank, which is the primary source of our training and validation complexes [36].”
BackgroundHullmann, J. E., Traynham, C. J., Coleman, R. C., & Koch, W. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.008 · Cited by 63
“This family of receptors is a major target of therapeutic intervention as most physiological processes require signaling through GPCRs including vision, smell, taste as well as neurologic, cardiovascular, endocrine and reproductive function [3].”
Electron Paramagnetic Resonance as a Tool for Studying Membrane Proteins
Sahu, I. D., & Lorigan, G. A. (2020) · Biomolecules · doi:10.3390/biom10050763 · Cited by 73
“Membrane proteins are targets of more than 50% of total modern food and drug administration (FDA) approved drugs [7,8].”
BackgroundRecent Advances in Chemoinformatics
Agrafiotis, D. K., Bandyopadhyay, D., Wegner, J. K., & van Vlijmen, H. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci700059g · Cited by 68
Nuclear receptors in inflammation control: Repression by GR and beyond
Chinenov, Y., Gupte, R., & Rogatsky, I. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.04.006 · Cited by 61
The emerging role of in vitro electrophysiological methods in CNS safety pharmacology
Accardi, M. V., Pugsley, M. K., Forster, R. P., Troncy, É., Huang, H., & Authier, S. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.03.008 · Cited by 71
In silico pharmacology: Drug membrane partitioning and crossing
Meo, F. D., Fabre, G., Berka, K., Ossman, T., Chantemargue, B., Paloncýová, M., Marquet, P., Otyepka, M., & Trouillas, P. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.030 · Cited by 71
Discovery and Characterization of Novel GPR39 Agonists Allosterically Modulated by Zinc
Sato, S., Huang, X., Kroeze, W. K., & Roth, B. L. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.106112 · Cited by 62
“G protein-coupled receptors (GPCRs) transduce extracellular stimuli into intracellular signals, have crucial roles in virtually all of human physiology, and are the targets for about one-third of currently marketed drugs (Overington et al., 2006; RaskAndersen et al., 2014).”
BackgroundRepurposing antifungal drugs for cancer therapy
Weng, N., Zhang, Z., Tan, Y., Zhang, X., Wei, X., & Zhu, Q. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2022.08.018 · Cited by 60
“The off-site target effects, which are traditionally considered to cause toxic side effects, result in unexpected efficacy for the treatment of cancer [103,104].”
BackgroundWhat can we learn from molecular dynamics simulations for GPCR drug design?
Tautermann, C. S., Seeliger, D., & Kriegl, J. M. (2014) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2014.12.002 · Cited by 67
“52A), but this site is directly connected to the receptor spanning water network which is conserved across class A GPCRs [81].”
BackgroundInfluentialG‐protein‐coupled receptor oligomers: two or more for what? Lessons from mGlu and GABAB receptors
Pin, J., Comps‐Agrar, L., Maurel, D., Monnier, C., Rives, M., Trinquet, E., Kniazeff, J., Rondard, P., & Prézeau, L. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.179978 · Cited by 79
“It is then not surprising that these receptors constitute the main target of drugs on the market and still represent the most promising targets for drug development (Hopkins & Groom, 2002; Overington et al. 2006).”
BackgroundRecent Trends and Observations in the Design of High-Quality Screening Collections
Renner, S., Popov, M., Schuffenhauer, A., Roth, H.-J., Breitenstein, W., Marzinzik, A., Lewis, I., Krastel, P., Nigsch, F., Jenkins, J., et al. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.15 · Cited by 60
Schlinkmann, K. M., Hillenbrand, M., Rittner, A., Künz, M., Strohner, R., & Plückthun, A. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.05.039 · Cited by 61
“50) that is crucial for activation of GPCRs.24 A version of D03 with restored DRY-motif [D03-L167R3.”
BackgroundInfluentialShuttling and translocation of heterotrimeric G proteins and Ras
Saini, D. K., Chisari, M., & Gautam, N. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.001 · Cited by 60
Nguyen, T., & Conboy, J. C. (2011) · Analytical Chemistry · doi:10.1021/ac2009614 · Cited by 60
Structure-Based Discovery of Selective Serotonin 5-HT 1B Receptor Ligands
Rodriguez, D. J., Brea, J. M., Loza, M. I., & Carlsson, J. (2014) · Structure · doi:10.1016/j.str.2014.05.017 · Cited by 65
“39 in the 5-HT2B structure (Figure 3A) (superscripts represent Ballesteros-Weinstein residue numbering for GPCRs; Ballesteros and Weinstein, 1995).”
BackgroundInfluentialBinding-Site Assessment by Virtual Fragment Screening
Huang, N., & Jacobson, M. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010109 · Cited by 67
“Several studies have predicted protein druggability on the basis of sequence and structural homology to known drug targets [1,2,8].”
BackgroundProverbio, D., Roos, C., Beyermann, M., Orbán, E., Dötsch, V., & Bernhard, F. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.05.031 · Cited by 60
Drug Discovery in a Multidimensional World: Systems, Patterns, and Networks
Dudley, J. T., Schadt, E. E., Sirota, M., Butte, A. J., & Ashley, E. A. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9214-6 · Cited by 65
Baronio, D., Gonchoroski, T., Castro, K., Zanatta, G., Gottfried, C., & Riesgo, R. (2014) · Annals of General Psychiatry · doi:10.1186/s12991-014-0034-y · Cited by 55
“From the four histaminergic receptors, H1R is the main target of most of the approved drugs [19] and is found in different tissues and cells, including the smooth muscle, brain, and lymphocytes [20,21].”
BackgroundNguemo, F., Šarić, T., Pfannkuche, K., Watzele, M., Reppel, M., & Hescheler, J. (2012) · Cellular Physiology and Biochemistry · doi:10.1159/000188069 · Cited by 69
Aging Biology and Novel Targets for Drug Discovery
Le Couteur, D. G., McLachlan, A. J., Quinn, R. J., Simpson, S. J., & de Cabo, R. (2012) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glr095 · Cited by 60
“whereas the rest are microbial targets (9).”
Metabolic Investigations of the Molecular Mechanisms Associated with Parkinson’s Disease
Powers, R., Lei, S., Anandhan, A., Marshall, D. D., Worley, B., Cerny, R. L., Dodds, E. D., Huang, Y., Panayiotidis, M. I., Pappa, A., et al. (2017) · Metabolites · doi:10.3390/metabo7020022 · Cited by 68
“FDA-approved metabolic inhibitors have been safely used as drugs in humans for decades [103].”
BackgroundSun, C. Y., Xuan, P., Zhang, T., & Ye, Y. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.2999084 · Cited by 65
Human metabolic network reconstruction and its impact on drug discovery and development
Ma, H., & Goryanin, I. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.002 · Cited by 59
Barukab, O., Ali, F., Alghamdi, W., Bassam, Y., & Khan, S. A. (2022) · Expert Systems with Applications · doi:10.1016/j.eswa.2022.116729 · Cited by 61
mGlu5negative allosteric modulators: a patent review (2010 – 2012)
Emmitte, K. A. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.760544 · Cited by 63
“10.1517/13543776.2013.760544 © 2013 Informa UK, Ltd. ISSN 1354-3776, e-ISSN 1744-7674 393 All rights reserved: reproduction in whole or in part not permitted In classifying approved therapeutic drugs according to their molecular targets, the most common gene family remains GPCRs [3].”
BackgroundInfluentialHomology Modeling of Class A G Protein-Coupled Receptors
Costanzi, S. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-588-6_11 · Cited by 70
“As a result of this opportunity for pharmacological intervention, GPCRs are the target of a large share of the currently marketed drugs (3) and are the object of intense studies aiming at the development of novel therapeutic strategies.”
BackgroundLi, L., Zhou, X., Ching, W., & Wang, P. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-501 · Cited by 62
“In fact, many enzymes have already been selected as drug targets [2,3].”
BackgroundSnooker: A Structure-Based Pharmacophore Generation Tool Applied to Class A GPCRs
Sanders, M. P. A., Verhoeven, S., de Graaf, C., Roumen, L., Vroling, B., Nabuurs, S. B., de Vlieg, J., & Klomp, J. P. G. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200088d · Cited by 60
Hsieh, J. M., Mercado, G., Madej, M. G., Bui, H., Kwon, S., & Abramson, J. (2010) · Protein Science · doi:10.1002/pro.365 · Cited by 59
“diseases and membrane proteins make up 40% of all pharmaceutical drugs targets currently under investigation.(1) Thus, a clear public health need exists to”
BackgroundGPCR agonist binding revealed by modeling and crystallography
Katritch, V., & Abagyan, R. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.08.001 · Cited by 60
Chen, X., Liu, M.-X., Cui, Q., & Yan, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043425 · Cited by 60
Bruce, V. J., Lopez‐Islas, M., & McNaughton, B. R. (2016) · Protein Science · doi:10.1002/pro.2926 · Cited by 61
Enhanced Cellular Entry and Efficacy of Tat Conjugates by Rational Design of the Auxiliary Segment
Zhang, P., Lock, L. L., Cheetham, A. G., & Cui, H. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400619v · Cited by 59
Bugge, K., Lindorff‐Larsen, K., & Kragelund, B. B. (2016) · FEBS Journal · doi:10.1111/febs.13793 · Cited by 63
Structure-guided SCHEMA recombination generates diverse chimeric channelrhodopsins
Bedbrook, C. N., Rice, A. J., Yang, K., Ding, X., Chen, S., LeProust, E. M., Gradinaru, V., & Arnold, F. H. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700269114 · Cited by 64
Alqinyah, M., & Hooks, S. B. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.10.007 · Cited by 66
Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs
Douguet, D. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00462 · Cited by 61
Alajmi, M. F., Hussain, A., Rehman, M. T., Khan, A. A., Shaikh, P. A., & Khan, R. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051492 · Cited by 60
“The benzimidazole core is also present inside the body as a component of Vitamin B12 [17].”
Ma, Z., Ajibade, A., & Zou, X. (2024) · Communications in Information and Systems · doi:10.4310/cis.241021221101 · Cited by 75
Direct and Propagated Effects of Small Molecules on Protein–Protein Interaction Networks
Cesa, L. C., Mapp, A. K., & Gestwicki, J. E. (2015) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2015.00119 · Cited by 74
“closely spaced amino acids to bind with high affinity are relatively easier to inhibit (Overington et al., 2006; Wells and McClendon, 2007; Meireles and Mustata, 2011; Jubb et al., 2012).”
BackgroundInteractive proteomics research technologies: recent applications and advances
Petschnigg, J., Snider, J. D., & Štagljar, I. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.09.001 · Cited by 58
Emerging Role of Surface Plasmon Resonance in Fragment-Based Drug Discovery
Navratilova, I. H., & Hopkins, A. L. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.128 · Cited by 65
Self-citationEmerging role of bioinformatics tools and software in evolution of clinical research
Bansal, P., Gill, S., Christopher, A., & Gupta, V. (2016) · Perspectives in Clinical Research · doi:10.4103/2229-3485.184782 · Cited by 65
“[8] This indicates that the current pharmaceutical research and development are dependent and relies on a small pool of drug targets, despite the availability of numerous genome data on human as well as the pathogen.”
BackgroundProtein epitope mimetic macrocycles as biopharmaceuticals
Luther, A., Moehle, K., Chevalier, É., Dale, G. E., & Obrecht, D. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.02.004 · Cited by 66
Aissaoui, D., Mlayah‐Bellalouna, S., Jebali, J., Abdelkafi-Koubaa, Z., Souid, S., Moslah, W., Othman, H., Luis, J., Ayeb, M. E., Marrakchi, N., et al. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.01.144 · Cited by 61
X-ray laser diffraction for structure determination of the rhodopsin-arrestin complex
Zhou, X. E., Gao, X., Barty, A., Kang, Y., He, Y., Liu, W., Ishchenko, A., White, T. A., Yefanov, O. M., Han, G. W., et al. (2016) · Scientific Data · doi:10.1038/sdata.2016.21 · Cited by 60
Burridge, K. M., Harding, B. D., Sahu, I. D., Kearns, M. M., Stowe, R. B., Dolan, M. T., Edelmann, R. E., Dabney‐Smith, C., Page, R. C., Konkolewicz, D., et al. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00041 · Cited by 57
Wang, S., König, G., ROTH, H. ‐., Fouché, M., Rodde, S., & Riniker, S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00775 · Cited by 59
Krishnarjuna, B., & Ramamoorthy, A. (2022) · Biomolecules · doi:10.3390/biom12081076 · Cited by 66
“More astoundingly, they account for 60% of drug targets [2].”
BackgroundAshtawy, H. M., & Mahapatra, N. R. (2015) · BMC Bioinformatics · doi:10.1186/1471-2105-16-s6-s3 · Cited by 63
“This is typically the case since, as it was mentioned earlier, 92% of drug targets are similar to known proteins [33].”
BackgroundNew avenues to target Wnt/β-catenin signaling
Verkaar, F., & Zaman, G. J. R. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.007 · Cited by 64
Kombarov, R. V., Altieri, A., Genis, D. V., Kirpichenok, M., Kochubey, V. V., Rakitina, N., & Titarenko, Z. Y. (2009) · Molecular Diversity · doi:10.1007/s11030-009-9157-5 · Cited by 57
Melchiorre, C., Bolognesi, M. L., Minarini, A., Rosini, M., & Tumiatti, V. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100293f · Cited by 63
Tricks of the trade used to accelerate high‐resolution structure determination of membrane proteins
Sonoda, Y., Cameron, A. D., Newstead, S. L., Omote, H., Moriyama, Y., Kasahara, M., Iwata, S., & Drew, D. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.015 · Cited by 69
“As more than 40% of small molecule drug targets are aimed at membrane proteins, each high-resolution structure is eagerly anticipated by both academia and the pharmaceutical industry [2].”
Atomic-level analysis of membrane-protein structure
Hendrickson, W. A. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3215 · Cited by 64
TMSEG: Novel prediction of transmembrane helices
Bernhofer, M., Kloppmann, E., Reeb, J., & Rost, B. (2016) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25155 · Cited by 63
The Isoxazole Ring and Its N‐Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics
Pairas, G., Perperopoulou, F., Tsoungas, P. G., & Varvounis, G. (2017) · ChemMedChem · doi:10.1002/cmdc.201700023 · Cited by 59
Selvaraj, G., Kaliamurthi, S., Kaushik, A. C., Khan, A., Wei, Y.-K., Cho, W. C. S., Gu, K., & Wei, D. (2018) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2018.09.004 · Cited by 62
Using macropinocytosis for intracellular delivery of therapeutic nucleic acids to tumour cells
Desai, A. S., Hunter, M. R., & Kapustin, A. N. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2018.0156 · Cited by 63
Nuclear receptors in podocyte biology and glomerular disease
Agrawal, S., He, C., & Tharaux, P. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00339-6 · Cited by 62
“Stretch reduces nephrin expression via an angiotensin IIAT(1)-dependent mechanism in human podocytes: effect of rosiglitazone.”
BackgroundArck, P., Tóth, B., Pestka, A., & Jeschke, U. (2010) · Biology of Reproduction · doi:10.1095/biolreprod.110.083550 · Cited by 62
“Food and Drug Administration-approved drugs [9].”
Single‐Molecule FRET of Membrane Transport Proteins
Bartels, K., Lasitza‐Male, T., Hofmann, H., & Löw, C. (2021) · ChemBioChem · doi:10.1002/cbic.202100106 · Cited by 54
Putting on molecular weight: Enabling cryo-EM structure determination of sub-100-kDa proteins
Wentinck, K., Gogou, C., & Meijer, D. H. (2022) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2022.09.005 · Cited by 59
Parasite neuropeptide biology: Seeding rational drug target selection?
McVeigh, P., Atkinson, L. E., Marks, N. J., Mousley, A., Dalzell, J. J., Sluder, A. E., Hammerland, L. G., & Maule, A. G. (2011) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2011.10.004 · Cited by 61
“…signalling, the G-protein coupled receptors (GPCRs) step forward as proteins that are highly ‘druggable’ with estimates that up to 50% of human medicines are directed at these proteins (Flower, 1999; Wise et al., 2002; Jacoby et al., 2006; Overington et al., 2006; Lagerström and Schiöth, 2008).”
BackgroundÍsberg, V., Andersen, K. B., Bisig, C., Dietz, G. P. H., Bräuner‐Osborne, H., & Gloriam, D. E. I. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500197a · Cited by 62
Xia, J., Jin, H., Liu, Z., Zhang, L., & Wang, X. S. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500062f · Cited by 53
Population patch clamp electrophysiology: a breakthrough technology for ion channel screening
Dale, T., Townsend, C. Y., Hollands, E. C., & Trezise, D. J. (2007) · Molecular BioSystems · doi:10.1039/b706152h · Cited by 56
Drug-therapy networks and the prediction of novel drug targets
Spiro, Z., Kovacs, I. A., & Csermely, P. (2008) · Journal of Biology · doi:10.1186/jbiol81 · Cited by 56
“Wide-range screens of existing drugs, seeking novel applications [2], combination therapy, i.”
BackgroundWenderski, T. A., Stratton, C. F., Bauer, R. A., Kopp, F., & Tan, D. S. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-2269-7_18 · Cited by 59
“For example, current small-molecule drugs address only about 1 % of the protein targets encoded in the human genome [4], and half of those target only four protein classes: rhodopsin-like Gprotein receptors, nuclear receptors, and voltage- and ligand-gated ion channels.”
BackgroundPan-Cancer Analyses of the Nuclear Receptor Superfamily
Long, M. D., & Campbell, M. J. (2015) · Nuclear Receptor Research · doi:10.11131/2015/101182 · Cited by 59
“Reflecting this central role, they represent the target for approximately 15% of all pharmacologic drugs [7].”
BackgroundBuchwald, P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00605 · Cited by 69
“, EC50 < 1 μM) with existing smallmolecule drugs having an average potency of 20 nM (Overington et al., 2006).”
BackgroundDrug design targeting active posttranslational modification protein isoforms
Meng, F., Liang, Z. T., Zhao, K., & Luo, C. (2020) · Medicinal Research Reviews · doi:10.1002/med.21774 · Cited by 61
“In contrast to this, the biological space (also termed as target space) features a smaller and discrete space, accounting for approximately 30,000 disease‐modifying genes.(5) The theoretical number of proteins with an average length of 300 amino‐acids, is about 20(300) by using the 20 different types of natural amino…”
BackgroundEnriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Salerno, A., Seghetti, F., Caciolla, J., Uliassi, E., Testi, E., Guardigni, M., Roberti, M., Milelli, A., & Bolognesi, M. L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00302 · Cited by 59
Antimicrobial peptides as promising antibiotic adjuvants to combat drug-resistant pathogens
Chen, C., Shi, J., Wang, D., Kong, P., Wang, Z., & Liu, Y. (2023) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2023.2186215 · Cited by 71
“Various studies have shown that enhancing the hydrophobicity of these peptides can improve their activity since it increases the rate of peptide penetration in the membranes (Overington et al. 2006; Pfalzgraff et al. 2018).”
BackgroundNanoscale monitoring of drug actions on cell membrane using atomic force microscopy
Li, M., Liu, L., Xi, N., & Wang, Y. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.28 · Cited by 61
Mammalian plasma membrane proteins as potential biomarkers and drug targets
Ručević, M., Hixson, D. C., & Josić, D. (2011) · Electrophoresis · doi:10.1002/elps.201100212 · Cited by 62
Open Innovation for Phenotypic Drug Discovery: The PD2 Assay Panel
Lee, J. A., Chu, S., Willard, F. S., Cox, K. L., Galvin, R. J. S., Peery, R. B., Oliver, S. E., Oler, J., Meredith, T. D., Heidler, S. A., et al. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111405379 · Cited by 62
Rational design of protein–protein interaction inhibitors
Rognan, D. (2015) · MedChemComm · doi:10.1039/c4md00328d · Cited by 61
Helleboid, S., Haug, C., Lamottke, K., Zhou, Y., Wei, J., Daix, S., Cambula, L., Rigou, G., Hum, D. W., & Walczak, R. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113497095 · Cited by 57
“Consistent with their key biological roles, nuclear receptors serve as important drug targets,(7) and NR ligands represent 10% to 15% of the present pharmacopoeia.(8) RAR-related receptors (RORs), originally identified by virtue of their homology to retinoic acid receptors (RARs), have gained broad attention because o…”
BackgroundNovel Tripod Amphiphiles for Membrane Protein Analysis
Chae, P. S., Kruse, A. C., Gotfryd, K., Rana, R. R., Cho, K. H., Rasmussen, S. G. F., Bae, H. E., Chandra, R., Gether, U., Guan, L., et al. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201301423 · Cited by 55
Broecker, J., Morizumi, T., Ou, W.-L., Klingel, V., Kuo, A., Kissick, D., Ishchenko, A., Lee, M.-Y., Xu, S.-L., Makarov, O., et al. (2018) · Nature Protocols · doi:10.1038/nprot.2017.135 · Cited by 50
Drug design for ever, from hype to hope
Seddon, G. M., Lounnas, V., McGuire, R., van den Bergh, T., Bywater, R. P., Oliveira, L., & Vriend, G. (2012) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9519-9 · Cited by 58
“Of the more than twenty thousand protein types in our body less than five hundred are targeted by all these medicines [6].”
BackgroundNon-genomic effects of nuclear receptors: insights from the anucleate platelet
Unsworth, A. J., Flora, G. D., & Gibbins, J. M. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy044 · Cited by 54
PPAEDTI: Personalized Propagation Auto-Encoder Model for Predicting Drug-Target Interactions
Li, Y.-C., You, Z., Yu, C.-Q., Wang, L., Wong, L., Hu, L., Hu, P., & Huang, Y. (2022) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2022.3217433 · Cited by 60
“However, the existing data of known DTIs is just the tip of the iceberg of the complete potential protein targets for drug molecules and is still very limited for drug R&D [2].”
BackgroundHigh-throughput Oligopaint screen identifies druggable 3D genome regulators
Park, D. S., Nguyen, S. C., Isenhart, R. L., Shah, P. P., Kim, W., Barnett, R. J., Chandra, A., Luppino, J. M., Harke, J., Wai, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06340-w · Cited by 52
Retinal Ligand Mobility Explains Internal Hydration and Reconciles Active Rhodopsin Structures
Leioatts, N., Mertz, B., Martínez‐Mayorga, K., Romo, T. D., Pitman, M. C., Feller, S. E., Grossfield, A. M., & Brown, M. F. (2014) · Biochemistry · doi:10.1021/bi4013947 · Cited by 58
A structural biology view of target drugability
Egner, U., & Hillig, R. C. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.4.391 · Cited by 56
“The size of the training set varies between 20 and 100 structures, both from PDB entries (mostly crystal but also model structures) and internal sources [23,40,50,51] .”
BackgroundInfluentialvan der Lee, M. M. C., Bras, M., van Koppen, C. J., & Zaman, G. J. R. (2008) · SLAS DISCOVERY · doi:10.1177/1087057108326144 · Cited by 54
“G RECEPTORS (GPCRS) are one of the most successful single drug target classes at present, as evidenced by the fact that one fourth of marketed medicines interact with these proteins.(1) Not surprisingly, many pharmaceutical industries continue to actively pursue high-throughput screening (HTS) on large chemical compou…”
BackgroundNebbioso, A., Pereira, R., Khanwalkar, H., Matarese, F., García‐Rodríguez, J., Miceli, M., Logie, C., Kedinger, V., Ferrara, F., Stunnenberg, H. G., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0525 · Cited by 59
Memprot : a program to model the detergent corona around a membrane protein based on SEC–SAXS data
Pérez, J., & Koutsioubas, A. G. (2014) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004714016678 · Cited by 54
“About 25% of genes encode membrane proteins (Wallin & von Heijne, 1998) and they are the target of more than 50% of modern therapeutic agents (Overington et al., 2006).”
BackgroundIdentification of human drug targets using machine-learning algorithms
Kumari, P., Nath, A., & Chaube, R. (2014) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2014.11.008 · Cited by 56
Development of Protease Inhibitors and the Fight with Drug‐Resistant HIV‐1 Variants
Mitsuya, H., Maeda, K., Das, D., & Ghosh, A. K. (2008) · Advances in pharmacology · doi:10.1016/s1054-3589(07)56006-0 · Cited by 54
Simplified proteomics approach to discover protein–ligand interactions
Chang, Y., Schlebach, J. P., VerHeul, R., & Park, C. (2012) · Protein Science · doi:10.1002/pro.2112 · Cited by 55
Targeting G protein coupled receptor-related pathways as emerging molecular therapies
Ghanemi, A. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.07.007 · Cited by 53
“Many pharmaceutical companies are working on the identification of agents that target GPCRs (Lagerstrom and Schioth, 2008; Overington et al., 2006) and advances about factors such as those influencing GPCRs’ activity (Ghanemi et al.”
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.